You are here

Home » Reports

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 332 results
 
  • Record 1 TO 332

  1. N/A

    SBC: ACCESS PHARMACEUTICALS, INC.            Topic: N/A

    N/A

    STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health

  2. N/A

    SBC: Introgen Therapeutics, Inc.            Topic: N/A

    N/A

    STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health

  3. N/A

    SBC: Introgen Therapeutics, Inc.            Topic: N/A

    N/A

    STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health

  4. Therapy for gastrointestinal disorders

    SBC: AGENNIX, INC.            Topic: N/A

    DESCRIPTION (Applicant's Abstract): The overall goal of this research proposal is to determine the effectiveness of recombinant human lactoferrin (rhLF) for treating gastrointestinal (GI) disorders. This Phase II proposal will focus on the ability of rhLF to treat the 01 side effects of non-steroidal anti-inflammatory drugs (NSAIDs), a class of drugs widely-us ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health

  5. Therapy for gastrointestinal disorders

    SBC: AGENNIX, INC.            Topic: N/A

    DESCRIPTION (Applicant's Abstract): The overall goal of this research proposal is to determine the effectiveness of recombinant human lactoferrin (rhLF) for treating gastrointestinal (GI) disorders. This Phase II proposal will focus on the ability of rhLF to treat the 01 side effects of non-steroidal anti-inflammatory drugs (NSAIDs), a class of drugs widely-us ...

    STTR Phase II 2001 Department of Health and Human ServicesNational Institutes of Health

  6. Drug Delivery System for Superficial Mycoses

    SBC: Biomedical Development Corporation            Topic: N/A

    DESCRIPTION (Provided by the applicant): The goal of this project is to establish the safety and efficacy of a unique drug delivery system for use as a sustained-release, antifungal skin preparation for the treatment of superficial mycoses. The lifetime risk of acquiring a superficial mycotic infection is estimated to be between 10 and 20 percent. In the U.S., annu ...

    STTR Phase II 2001 Department of Health and Human ServicesNational Institutes of Health

  7. Drug Delivery System for Superficial Mycoses

    SBC: Biomedical Development Corporation            Topic: N/A

    DESCRIPTION (Provided by the applicant): The goal of this project is to establish the safety and efficacy of a unique drug delivery system for use as a sustained-release, antifungal skin preparation for the treatment of superficial mycoses. The lifetime risk of acquiring a superficial mycotic infection is estimated to be between 10 and 20 percent. In the U.S., annu ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health

  8. Gene Expression in Engineered Human Skin

    SBC: Dermigen, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Exposure of humans to sunlight produces adaptive and pathological responses in the skin, including erythema (inflammation), tanning, photoaging, photoallergy and carcinogenesis. These responses involve the modulation of gene expression and excessive exposure can result in mutation and tumorigenesis. The effects produced b ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health

  9. ADF, novel cytokine PPAR-gamma regulator from fat cells

    SBC: GENETEX, INC.            Topic: N/A

    DESCRIPTION (Scanned from the Applicant's Abstract): Obesity is a major risk factor for diabetes mellitus (type 2; NIDDM). Fat cells secrete both diabetes promoting molecules (fatty acids; TNF-alpha) and at least one molecule that may be antidiabetic (leptin). We have partially purified a new protein (cytokine) which is also secreted by mature adipocytes, Adipocyte Diffe ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health

  10. ULTRASONIC BLOOD VISCOMETER

    SBC: INDUS INSTRUMENTS            Topic: N/A

    DESCRIPTION (Verbatim from Applicant's Abstract): Blood viscosity is altered in diseases such as sickle cell anemia, hypertension, and atherosclerosis and also during coagulation, but its measurement requires complex and expensive instrumentation and is thus rarely done. We propose to develop an ultrasonic technique to simplify this measurement using small samples o ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government